{"entity":{"id":"ai-cancerch","kind":"drug","name":"ai-CANCERCH","aka":[],"tldr":"GC Genome's blood test from South Korea, launched in 2023 for six cancers, built on a method published with KAIST.","summary":"The underlying method (Bae et al., Nature Communications 2023, GC Genome with KAIST) used whole-genome sequencing of 2,125 cancer samples of nine types and 1,241 controls and reports detection of early-stage cancers with sensitivity comparable to late stage, without headline figures in the abstract. GC Genome's release of 27 November 2025 says the test launched in September 2023 for six cancers and was planned to expand to ten in January 2026, and quotes 91.1% performance at 95% specificity from the paper; whether the expansion happened was not confirmed. No regulatory status or price was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Bae et al., Nature Communications 2023","url":"https://doi.org/10.1038/s41467-023-37768-3"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","fragmentomics"],"targets":[],"drugs":[],"companies":["gc-genome"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"ai-CANCERCH","modality":"Multi-cancer blood test (low-coverage whole-genome sequencing, fragmentomics)","mechanism":"Low-depth whole-genome sequencing of cell-free DNA, modelling mutation distribution and chromatin organisation patterns of tumour types to detect cancer and localise it.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ai-cancerch/","neighbours":{"technology":[{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"gc-genome","kind":"company","name":"GC Genome","route":"/companies/gc-genome/"}]}}